Inadequate Disease Control with Current Therapies Among Patients with a History of Moderate-to-Severe Atopic Dermatitis.

INTRODUCTIONThis study assessed disease control and symptom burden among US adults with moderate-to-severe atopic dermatitis (AD) treated with topical-only or systemics (conventional [corticosteroids/immunosuppressants]/advanced [biologics/JAKi]) ± topicals.

METHODSData were obtained from the Adelphi Atopic Dermatitis Disease Specific Programme, a cross-sectional real-world survey (August 2022-March 2023). Physicians completed patient record forms, and patients completed quality-of-life and symptom questionnaires. Uncontrolled AD was defined by physician-reported flares, dissatisfaction with control, and/or deteriorating disease. Patient-reported outcomes included the Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), and Work Productivity and Activity Impairment (WPAI-AD).

RESULTSAmong 619 analyzed patients (mean age 40.5, 50% female), 30.2% had uncontrolled AD-36.4% treated with topicals-only and 63.6% with systemics ± topicals. Patients with uncontrolled AD on systemics reported higher symptom burden (DLQI 10.0, POEM 11.8) and activity impairment (WPAI 30.9) versus topicals-only (DLQI 3.3, POEM 8.7, WPAI 13.9). Absenteeism was notable in systemic-treated patients (12.1) but absent in topical-only groups. Patients with controlled AD showed lower symptom scores and better quality of life (QoL) across all treatments. Conventional systemics were associated with greater burden than advanced systemics.

CONCLUSIONDespite available treatments, a substantial proportion of patients with moderate-to-severe AD remain uncontrolled, experiencing significant symptom burden and impaired QoL-underscoring the need for improved therapeutic strategies.

Abstract from PubMed